Home
overview

SMi’s 8th Annual Conference
Pharmaceutical Microbiology UK
January 21 - 22, 2019 | London, United Kingdom
-------------------------------------------------------------------------

The pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods, revisions being made to regulations in the industry, enhanced knowledge of the human microbiome, and novel testing methods, this industry is ever expanding. In fact, the value of the rapid microbiology testing market is expected to reach USD 6.2 Billion by 2022, expanding at a CAGR of 7.3% from 2016 to 2022.


Join industry experts to discuss and analyze the latest advances and challenges within the industry. Network with industry professionals, discuss the revision of Annex 1, gain insight into novel rapid microbiology methods, explore case studies on contamination control and consider the issues surrounding data integrity.
 

Developing on last years’ success, Pharmaceutical Microbiology UK 2019 will bring together industry experts to discuss and analyze the latest advancement and challenges within pharmaceutical microbiology. Discover how you can keep up with regulatory changes, and maintain the utmost efficiency during production and testing.

At the 8th Annual Pharmaceutical Microbiology Conference, you will gain insight into:

  • Challenges in development of a contamination control strategy for different product types
  • A series of learning experiences within contamination from Boehringer Ingelheim
  • The use of vaporized hydrogen peroxide bio-decontamination technology in microbiology contamination control
  • Case studies in deinococcus and fungal and bacterial spores in cleanrooms
  • Influence of temperature of incubation on results of microbiological environmental monitoring
  • Risk mitigation strategies for animal-derived raw materials

Testimonials from previous attendees:
“Great presentations of relevance to pharmaceutical microbiology. Some valuable learning and networking’”- AstraZeneca
“I really enjoyed the conference and how most presentations linked well with the other topics presented”- MHRA
“Well organised conference with a good variety of topics!!” – GSK
 

Key Job Titles: 

Senior Microbiologist, Lead Scientist, Laboratory Manager, QA Specialist Drug Substance External Manufacturer, Business Development Manager – Testing, Pharmaceutical Microbiology Consultant, Higher Pharmacopoeial Scientist, Analytical Standards Specialist

Global Presence:

Attendees from all over the world attend our events. Gain insight from representatives from the UK, Europe and the USA.

Alexion; Alexion Pharmaceutical, Inc.; Allergan Biologics Ltd; AllergyTherapeutics; Astrazeneca; Battelle Memorial Institute; Bettelle Pacific N W Lab; Biomerieux; bioMérieux SA; Biovian Ltd; Boehringer Ingelheim France; Bristol Myers Squibb; Confarma France S A R L; David P Elder Consultancy; GE Healthcare; GSK; Ith Pharma; Lonza Biologics plc; Lonza Cologne GmbH; Lonza Incorporated; Merck; Merial; Merial Animal Health; Mettler-Toledo Ltd; Mettler-Toledo Thornton; MHRA; MIcrobiologics; Nottingham Trent University; Param Enterprises; Paul Ehrlich Institut; Pfizer; Pfizer Inc; PMT (GB) Ltd; PrEP Biopharm; Public Health England; Reading Scientific Services Limited; Regeneron Ireland UC; Regeneron Pharmaceuticals Inc.; Roche; Roche Diagnostics Deutschland GmbH; Samedan Ltd ; Sanofi; Sanofi Pharma; seqirus; Shire Laboratories; Steris; STERIS Corporation; The Cell and Gene Therapy Catapult; TSI;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Olivier Chancel

Olivier Chancel, Sterility and Aseptic Process Assurance Expert, Boehringer Ingelheim

9:10 Challenges in development of a contamination control strategy for different product types

Di Morris

Di Morris, Senior Manager, Team Leader, Vaccines Quality Audit, GSK

  • What is expected to be included in a contamination control strategy as a GMP requirement outlined in the revised (draft) Annex 1
  • Contamination control strategy for different product types: Sterile Non-Hazardous, Aseptic Toxic, Aseptic Highly Potent (including ADC’s), Aseptic Sensitising (Hormones)
  • Contamination control strategy and linkage to cross contamination
  • 9:50 Series of learning experiences on contaminations: poor understanding of some microbiological aspects associated with still common preventive maintenance issues

    Olivier Chancel

    Olivier Chancel, Sterility and Aseptic Process Assurance Expert, Boehringer Ingelheim

  • Damaged gaskets in mixers
  • Bad setting of travel stops
  • Bad assembly of diaphragm valves
  • Inappropriate inner diameter of gaskets
  • Silicone sealants of panels and self-contained clean rooms
  • Pressure differentials of hydrophobic filters
  • How tight is hand tight?
     
  • 10:30 Morning Coffee

    11:00 Quality risk management of clean room garments and sterile packaging solutions for materials, equipment, components and ancillary items for aseptic processing

    Thierry Wagner

    Thierry Wagner, Regulatory Affairs Director Europe, Middle East and Africa, Dupont De Nemours (Luxembourg) S A
    View Bio

  • Assessing microbial barrier properties of porous materials
  • Particulate release is a key risk factor to consider: tests for ranking of materials
  • Implementing a contamination control strategy covering the entire product life cycle: from quality-by-design, through qualifications and risk assessments of implemented solutions to thorough operations management
  • 11:40 The strengths and weaknesses of Vaporised Hydrogen Peroxide as a bio-contamination control agent in GMP applications

    James  Drinkwater

    James Drinkwater, Chairman, Pharmaceutical and Healthcare Sciences Society

  • Application of VHP/vH202 in bio-contamination control
  • Strengths considering principle attributes and qualification as a broad spectrum sporicidal agent
  • Weaknesses and fragility considered in the MHRA log
  • Principle scientific facts and variance in H202 vapour delivery and cycle control
  • Does the attention of the regulatory agencies mean the ‘Death of the VHP process’ or is the ‘Death of scientific ignorance’ the real purpose of the Blog?

     

  • 12:20 Networking Lunch

    13:30 Case studies in deinococcus and fungal and bacterial spores in cleanrooms

    Jim Polarine

    Jim Polarine, Senior Technical Service Manager, STERIS Corporation

  • The complexities of CAPA excursion investigations
  • Ways to proactively limit bacterial and mold spore contamination from incoming items into cleanrooms
  • Current industry regulations in the US and Europe with relation to sporicides and disinfectants
  • Recent case studies on new antimicrobial chemistries and their performance against fungal and bacterial spores in cleanrooms
  • 14:10 Mold contamination challenges

    Ziva Abraham

    Ziva Abraham, Founder and CEO, Microrite

  • Understanding mold
  • Understanding disinfection and disinfectant qualification as it relates to mold
  • Investigation mold contaminations
  • Clinical relevance of objectionable mold

     

  • 14:50 Afternoon Tea

    15:20 Case study on using contamination recovery rates to measure performance and improve contamination control

    Alexander Stoll

    Alexander Stoll, Vice President, Head of Competence Center Microbiology and Aseptic Techniques, Fresenius Kabi

  • Use of contamination recovery rates as an effective tool for cleanroom monitoring
  • How to use these metrics to improve your contamination control
  • Case study showing step change in the metrics, and thus showing improvement in contamination control
     
  • 16:00 Case study: Use of applied methodology for the transfer of moist heat sterilised parts from an autoclave to RABS aseptic processing line with Grade A continuity

    Tim Eaton

    Tim Eaton, Sterile Manufacturing Specialist, AstraZeneca
    View Bio

  • Principles of Grade A continuity and how to implement solutions in process operations
  • Definition, classification and qualification of localised uni-directional airflow used as aerodynamic protection of autoclave unload and loading of transfer carts and unload of transfer carts into RABS aseptic process line
  • Transfer cart case study: maintaining sterile integrity of sterilised parts in transfers
  • 16:40 Smoke studies: Misconceptions and regulatory implications

    Morgan  Polen

    Morgan Polen, Contamination Control and Cleanroom Expert, Microrite, Inc.

  • Regulatory expectations and recommendations
  • Myths and facts about AFV- where mistakes are made
  • Discussion of FDA 483s related to smoke studies
  • 17:20 Influence of temperature of incubation on results of microbiological environmental monitoring

    Philippe Dutot

    Philippe Dutot, Sterility Assurance Specialist, Novo Nordisk

  • Regulatory perspective
  • Bibliography review focused on “in situ” studies
  • Results of a one-year comparison study between two incubation regimens (30-35°C for 3 days vs 20-25°C for 5 days) for the monitoring of a pharmaceutical production classified area
  • 18:00 Chairman's Closing Remarks and Close of Day One

    Olivier Chancel

    Olivier Chancel, Sterility and Aseptic Process Assurance Expert, Boehringer Ingelheim

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    James  Drinkwater

    James Drinkwater, Chairman, Pharmaceutical and Healthcare Sciences Society

    9:10 Mycoplasma safety testing of biopharmaceuticals and ATMPs by rapid NAT-based detections methods – Current regulations, challenges and trends

    Renate Rosengarten

    Renate Rosengarten, Professor and Chair of Bacteriology and Hygiene, University of Veterinary Medicine Vienna

  • Why do mycoplasmas pose such a challenge in implementing safety concepts for biopharmaceuticals and ATMPs
  • Haemoplasmas as potential contaminants of ATMPs
  • A risk-based approach for the validation and implementation of rapid NAT-based mycoplasma safety testing
  • How to tailor a product-specific mycoplasma NAT method validation study to meet the regulatory requirement
     
  • 9:50 Risk mitigation strategies for animal-derived raw materials

    Rosemary Versteegen

    Rosemary Versteegen, CEO, International Serum Industry Association

  • Risk mitigation in sourcing
  • Does geography matter?
  • Where did that serum come from?
  • Robust viral clearance steps
  • Overview of options
  • Review of what works and why

     

  • 10:30 Morning Coffee

    11:00 Innovative sampling strategies to retrieve the invisible

    Sonia  Allibardi

    Sonia Allibardi, Market Access Manager, Copan Italia SpA
    View Bio

  • What swab to use for surface monitoring of environmental microbial contamination?
  • The hidden technology of COPAN FLOQSwabs®
  • Innovative approaches for sampling
  • 11:40 Current and Novel Viral Safety Strategies Applied to the Manufacture of Plasma-Derived Medicinal Products (PDMPs)

    Steve Simoneau

    Steve Simoneau , Biological Safety Project Manager, The LFB Group

  • Current challenges and methods of adventitious agent clearance
  • Novel strategies for safeguarding patients
  • Quality by Design (DoE approach)
  • Next Generation Sequencing
  • 12:20 Networking Lunch

    14:10 Rapid microbiological methods

    Andrew Bartko

    Andrew Bartko, Research Leader, Battelle Memorial Institute

  • Design, validation and implementation of RMM
  • Acceptance of RMM by regulatory bodies
  • RMM from a business perspective
  • Case study of RMM implementation
  • 14:50 Afternoon Tea

    15:20 Return of experience on implementation of mycoplasma alternative method to release vaccines

    Marine Marius

    Marine Marius, Scientist, Analytical Research and Development Europe, Sanofi Pasteur
    View Bio

  • Implementation of a Rapid Microbial Method for mycoplasma testing
  • Journey of an investigational vaccine
  • Journey of a legacy product
  • Return of experience
  • 16:00 Future of endotoxin testing in pharmaceutical industries

    Thierry Bonnevay

    Thierry Bonnevay, Microbiology Platform Head Analytical Research & Development, Sanofi Pasteur
    View Bio

  • Trends in endotoxin testing
  • Evaluation and implementation of new methods
  • Results of an internal evaluation
  • What’s next?
  • 16:40 How Dead is Dead? The problem of VBNC bacteria

    Bill Keevil

    Bill Keevil, Scientific Advisor to the House of Commons Select Committee on Science & Technology, Head of the Microbiology Group and Director of the Environmental Healthcare Unit. University of Southampton, UK, University of Southampton

  • Defining what VBNC bacteria are
  • Tools to identify VBNC bacteria and biofilms
  • When disinfectants or sanitizers mislead
  • Animal models to confirm VBNC infectivity
  • 17:20 Chairman's Closing Remarks and Close of Day Two

    James  Drinkwater

    James Drinkwater, Chairman, Pharmaceutical and Healthcare Sciences Society

    +

    FEATURED SPEAKERS

    Di Morris

    Di Morris

    Senior Manager, Team Leader, Vaccines Quality Audit, GSK
    James  Drinkwater

    James Drinkwater

    Chairman, Pharmaceutical and Healthcare Sciences Society
    Jim Polarine

    Jim Polarine

    Senior Technical Service Manager, STERIS Corporation
    Olivier Chancel

    Olivier Chancel

    Sterility and Aseptic Process Assurance Expert, Boehringer Ingelheim
    Renate Rosengarten

    Renate Rosengarten

    Professor and Chair of Bacteriology and Hygiene, University of Veterinary Medicine Vienna
    Tim Eaton

    Tim Eaton

    Sterile Manufacturing Specialist, AstraZeneca

    Alexander Stoll

    Vice President, Head of Competence Center Microbiology and Aseptic Techniques, Fresenius Kabi
    Alexander Stoll

    Bill Keevil

    Scientific Advisor to the House of Commons Select Committee on Science & Technology, Head of the Microbiology Group and Director of the Environmental Healthcare Unit. University of Southampton, UK, University of Southampton
    Bill Keevil

    Di Morris

    Senior Manager, Team Leader, Vaccines Quality Audit, GSK
    Di Morris

    James Drinkwater

    Chairman, Pharmaceutical and Healthcare Sciences Society
    James  Drinkwater

    James Cannon

    Head of OEM and Markets, Mettler-Toledo Thornton
    James Cannon

    Jim Cannon is Head of OEM and Markets at Mettler-Toledo Thornton, he has a B.S. in Biology, degrees in Microbiology and Biophysics, and an MBA in Marketing and International Management. Mr. Cannon has over 35 years of experience in the management, design and development of ultrapure water treatment and technology. This includes measuring differential conductivity and UV oxidation for the detection of TOC in UPW and the design and commercialisation of electrodeionisation modules. Mr Cannon is currently involved in the standards and regulatory organisations for the Semiconductor, Photovoltaic and Pharmaceutical markets, and the commercialisation of alternative microbial technology.
     

    Jim Polarine

    Senior Technical Service Manager, STERIS Corporation
    Jim Polarine

    Marine Marius

    Scientist, Analytical Research and Development Europe, Sanofi Pasteur
    Marine Marius

    Marine Marius is Scientist in the Analytical Sciences department of Sanofi Pasteur in the Microbiology/Virology platform. She leads the development, validation and implementation of rapid microbiology methods (bacteriology and molecular biology) for legacy and investigational products. She is an internal SME in endotoxin, mycoplasma and mycobacteria testing. Marine holds a M.Sc. in Biotechnology and Applied Microbiology from ESIL University (Ecole Supérieure d’Ingénieurs de Luminy) in France.

    Morgan Polen

    Contamination Control and Cleanroom Expert, Microrite, Inc.
    Morgan  Polen

    Olivier Chancel

    Sterility and Aseptic Process Assurance Expert, Boehringer Ingelheim
    Olivier Chancel

    Philippe Dutot

    Sterility Assurance Specialist, Novo Nordisk
    Philippe Dutot

    Renate Rosengarten

    Professor and Chair of Bacteriology and Hygiene, University of Veterinary Medicine Vienna
    Renate Rosengarten

    Rosemary Versteegen

    CEO, International Serum Industry Association
    Rosemary Versteegen

    Sonia Allibardi

    Market Access Manager, Copan Italia SpA
    Sonia  Allibardi

    Molecular biologist with a specialization degree in Biochemistry Science. Currently working in the Scientific Team of COPAN as Market Access Manager for the implementation of innovative Medical Devices in pre-analytics focusing on Italy, Eastern Europe and Asia Pacific Market. Her professional life started in a research Cardiovascular Physiology laboratory at San Raffaele Scientific Institute, Milan Italy, where she worked for more than 10 years and published scientific papers on International Journals. The objective of her research was the evaluation of myocardial metabolism in hypoxic and ischemic heart. In 2011, thanks to the “Mad Cow Disease”, she started a new job in Biorad Company. She spent three years as scientific product specialist in the life science division for Italy and Southern Europe (Spain, Greece, Portugal). She moved to Cepheid Europe for five years where her main topics were: Women’s Health, Hospital Acquired Infection and Tuberculosis.

    Steve Simoneau

    Biological Safety Project Manager, The LFB Group
    Steve Simoneau

    Thierry Bonnevay

    Microbiology Platform Head Analytical Research & Development, Sanofi Pasteur
    Thierry Bonnevay

    Thierry Bonnevay obtained his Pharm. D pharmacist with special degree in Industrial Pharmaceutical Microbiology in 1996. He joined Sanofi Pasteur in 1997 as QC Bacteriology manager in Industrial Operation. He joined the Analytical Research and Development Department in 2004 and since that time he worked in the development, the validation and the implementation of Microbiology alternatives methods based on bacteriology and molecular biology for commercialized products and clinical products. He is currently Microbiology Platform Leader in Analytical R&D and part of the USP expert panel in Modern Microbiological Methods (MMM) since 2015. He is member of Groups of Experts at the European Pharmacopoeia EDQM Group 1 Microbiology since November 2016 and Working Party Bacterial Endotoxin Test (WP BET) since November 2017.

    Thierry Wagner

    Regulatory Affairs Director Europe, Middle East and Africa, Dupont De Nemours (Luxembourg) S A
    Thierry Wagner

    Thierry Wagner has spent over 30 years working for DuPont in its polyester films and nonwovens businesses in a variety of assignments ranging from process development and project management to operations and business management. He is chairman of the board of the Sterile Barrier Association (SBA), member of the Parenteral Drug Association (PDA) and actively involved in various ISO and CEN technical committees on medical and pharmaceutical packaging like ISO TC198 “Sterilization of Health Care Products” on Packaging (ISO 11607) as well as Aseptic Processing, CEN TC102 “Sterilizers for Medical Purposes” (packaging and VH2O2 sterilisers) and ISO TC76 “Transfusion, infusion and injection equipment for medical and pharmaceutical use”. Thierry is also a member of ISO/TC 210 in charge of ISO 13485, ASTM Committee F02 – Flexible Barrier Packaging and of the CEN ABHS (Advisory Board for Healthcare Standards - Europe).
    Thierry Wagner earned a master’s degree in mechanical and process engineering from ETH Zürich in Switzerland. He is a featured speaker at international conferences and seminars on medical and pharmaceutical packaging regulatory aspects.

    Tim Eaton

    Sterile Manufacturing Specialist, AstraZeneca
    Tim Eaton

    Tim Eaton B.Sc. (chemistry) has over 25 years’ experience of sterile manufacture with Zeneca Pharmaceuticals and AstraZeneca. During this time he has had extensive roles in technical support, production management and specialist activities for aseptically prepared products. He has had responsibilities for the design, construction, start up and validation of multimillion pound aseptic manufacturing facilities and has managed the introduction, technical transfer and scale up activities for a number of sterile products. He has published a number of papers relating to cleanroom activities and has also presented at various industry forums in Europe, Asia and the US.
    In his current role of Sterile Manufacturing Specialist he has responsibilities for the derivation, optimisation and implementation of best practices for aseptically prepared products. He sits on LBI/30, the British Committee for Cleanroom Technology.
     

    Ziva Abraham

    Founder and CEO, Microrite
    Ziva Abraham

    Sponsors and Exhibitors

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Sponsors and Exhibitors


    bioMérieux

    Sponsors and Exhibitors
    http://www.biomerieux.com/en/industry-solutions

    A world leader in the field of in vitro diagnostics for over 50 years, bioMérieux is present in more than 150 countries through 43 subsidiaries and a large network of distributors. In 2017, revenues reached €2.3 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.


    COPAN

    Sponsors and Exhibitors
    http://www.copangroup.com

    With a rightful reputation for innovation, COPAN is the world leading manufacturer of collection and transport systems. In like manner, COPAN’s collaborative approach to pre-analytics has resulted in the development of FLOQSwabs®, ESwab®, UTM® and modular laboratory automation, WASP® and WASPLab®. For further information on COPAN, visit www.copangroup.com


    METTLER TOLEDO

    Sponsors and Exhibitors
    http://www.mt.com

    METTLER TOLEDO is a leading manufacturer of quality weighing, analytical, and measuring solutions serving a diverse range of industries in laboratory, industrial and food retailing environments.


    METTLER TOLEDO has over 60 years of experience producing liquid process and ultrapure water analytics measurement solutions that allow manufacturing companies to control production through in-line, on-line or at-line analytical measurements.


    Our portfolio of analytical solutions includes pH, ORP, dissolved oxygen, dissolved CO2, turbidity, conductivity/resistivity, dissolved ozone, total organic carbon, microbial contamination, sodium ionic contamination, silica concentration, chloride and sulphate analysis.



    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out